Scinai Immunotherapeutics
SCNI
9 hedge funds and large institutions have $717K invested in Scinai Immunotherapeutics in 2022 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 5 closing their positions.
369% more capital invested
Capital invested by funds: $153K → $717K (+$564K)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
25% less funds holding
Funds holding: 12 → 9 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$1.66M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$131K |
| 3 |
Morgan Stanley
New York
|
+$4.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Envestnet Asset Management
Chicago,
Illinois
|
-$58K |
| 2 |
TPWA
TRUE Private Wealth Advisors
Salem,
Oregon
|
-$34K |
| 3 |
Renaissance Technologies
New York
|
-$13K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$10K |
| 5 |
Millennium Management
New York
|
-$9K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SM
1
Sabby Management
Miami Beach,
Florida
| $653K | +$1.66M | +22,056 | New |
|
|
2
Citadel Advisors
Miami,
Florida
| $51.9K | +$131K | +1,746 | New |
|
|
3
Morgan Stanley
New York
| $8.34K | +$4.21K | +56 | +25% |
|
4
Credit Agricole
Montrouge Cedex,
France
| $1.25K | – | – | – |
|
5
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | – | – | – |
|
6
UBS Group
Zurich,
Switzerland
| $888 | -$3.76K | -50 | -63% |
|
|
APC
7
Aspire Private Capital
Cornelius,
North Carolina
| $474 | – | – | – |
|
|
GRP
8
Global Retirement Partners
San Rafael,
California
| $148 | – | – | – |
|
9
Wells Fargo
San Francisco,
California
| $59 | – | – | – |
|
|
NC
10
NewSquare Capital
Newtown Square,
Pennsylvania
| $6 | – | – | – |
|
|
11
Envestnet Asset Management
Chicago,
Illinois
| – | -$58K | -792 | Closed |
|
|
TPWA
12
TRUE Private Wealth Advisors
Salem,
Oregon
| – | -$34K | -470 | Closed |
|
|
13
Renaissance Technologies
New York
| – | -$13K | -184 | Closed |
|
|
14
Geode Capital Management
Boston,
Massachusetts
| – | -$10K | -138 | Closed |
|
|
15
Millennium Management
New York
| – | -$9K | -123 | Closed |
|
SCNI Hedge Fund Activity: Q4 2022 in Review
9 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q4 2022, worth a combined $717K — up 369% from $153K a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of SCNI and 2 opened new positions — a net loss of 3 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Sabby Management, opening a new position worth an estimated $1.66M. The largest seller was Envestnet Asset Management, exiting entirely with an estimated $58K sold.
- 9 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q4 2022, down from 12 in Q3 2022.
- Funds reported $717K of Scinai Immunotherapeutics stock for Q4 2022, up 369% quarter-over-quarter.
- 2 funds opened new Scinai Immunotherapeutics positions in Q4 2022 and 5 closed out, a net change of -3 holders.
- The largest Scinai Immunotherapeutics buyer in Q4 2022 was Sabby Management, an estimated $1.66M added.
- The largest Scinai Immunotherapeutics seller in Q4 2022 was Envestnet Asset Management, an estimated $58K sold.
Based on aggregated 13F filings for Q4 2022.